INTRODUCTION
Malignancy is the most common disease around the world. An expected 1,606,670 new malignancy cases and 572,960 deaths happened in 2015 in the United States. 1 While chemotherapy remains a very fruitful weapon to treat malignancy, it is often associated with limitations and side effects. There is possibility of recurrence always and these malignancies can develop resistance to chemo-and radiation treatments. Common natural herbal compounds are broadly concentrated on to take in their particular parts in anticancer activities. 2, 3 Cuminosides is a hydrophobic polyphenolic compound got from the products of Syzigium cumini. Cuminosides is portrayed by an extensive variety of antibacterial, antifungal, antiviral, antioxidative, and antiproliferative exercises. [5] [6] [7] 9 Cuminosides has shown solid disease preventive action, including avoidance of tumor start, metastasis, and angiogenesis in test creature frameworks, against an extensive variety of tumor cells. 8, 10, 11 Cuminosides has pleiotropic properties that tweak various targets including proteins (thioredoxin reductase, cyclooxygenase 2 (COX-2), protein kinase C (PKC), 5-lipoxygenase, and tubulin), translation elements, development components and their receptors, cytokines, catalysts, and quality managing cell multiplication and apoptosis. [12] [13] [14] Many in vitro experiments exhibit that cuminosides restrains disease cells development (IC 50 , 50% cell development restraint) at convergence of 5-30 μM 3, 4, 8, 12, 14, 15 Cuminosides has a great degree safe profile in both creatures and people. 16, 17 Furthermore, a clinical study contained 15 patients with colorectal tumor demonstrated the growth was nonresponsive to cuminosides at a day by day measurements of 3.6 g (4 months). 21, 22 This study recommended there was no change in tumori-genesis or tumor markers and presumed that while cuminosides shows hostile to disease impacts at a centralization of 5-30 μM for 1 or 2 days, accomplishing these fixations at the tumor site in people not been expert because of cuminosides low bioavailability ( Figure 1 ) and higher metabolic action. Adjuvant cyclodextrin and some protected innovations were at first used to beat this issue. [23] [24] [25] Case in point, piperine is very prescribed in light of its inhibitory impacts of hepatic and intestinal glucuronidation, which advanced 154% and 2000% bioavailability in rats and people separately. [26] [27] [28] This shows the need of cuminosides exemplification in nanoparticles for disease treatment with conceivable focusing on moieties. 15, 18, 20 movement. 15 In the meantime, Bansal et al. 18, 19 present an exceptional survey essentially centered around the chemo-preventive part of nanoformulations and cuminosides stent innovations. Another survey article portrays cuminosides affected components in growth and ramifications of cuminosides nanoformulations in chemoprevention and treatment. 29 As we would see it, to date there is no particular, nitty gritty audit reporting the essential manufactured courses for arrangement of cuminosides nanoformulations, medication stacking wonder and the basic part of nanoparticle uptake by disease cells, anticancer exercises, tissue and bioavailability, and blood similarity. Therefore, this review aims to provide up-to-date contributions of cuminosides nanoformulations to cancer therapeutics; and further, to discuss how novel trends benefit cancer therapeutics.
Cuminoside nanoformulations
Nanoparticle innovation has been generally employed in medicine, including for tumor treatment. 30, 31, 32 As medication nanocarriers, nanoparticles have a few appealing elements: (i) enhanced epitome or solubilization of remedial medications for defensive and focused on conveyance, (ii) high surface to volume proportion empower alterations to surface useful gatherings keeping in mind the end goal to acquire broad adjustment and disguise, (iii) biocompatibility, unrivaled pharmacokinetics and negligible leeway from body, and (iv) controlled, boosts responsive, remote activation and on interest medication discharge properties. An expansive number of anticancer medication nanoformulations are as of now in clinical or preclinical advancement. A nanoformulations' percentage have been sanction by the FDA are at present accessible in the business sector. A nitty gritty rundown of affirmed plans is accessible. [33] [34] [35] Among these, the egg whites bound paclitaxel (PTX) poly (lactide-co-glycolide) (PLGA) nanoformulation (Abraxane™, http://www.abraxane.com/dtc/) is exceedingly effective in expanding the specificity and treatment effectiveness of different cancer(s).
Nanoparticle definitions of healthful fixings, for example, carotenoids, co-compound Q10, vitamins (A, D, E, K), phytosterols, minerals, and common concentrates are not new and have been accessible since 1960. 36 The primary rule in viable disease treatment is to accomplish the fancied centralization of helpful specialists at the tumor site to devastate particular malignant cells while minimizing poisonous quality to typical cells. 37, 40 
Cuminosides Encapsulation and Release Characteristics
Cuminosides drug loading is connected with the kind of nanoparticle and preparative system utilized ( Table 2 ). The medication stacking can be controlled by exemplification proficiency which gives the rate of medication added to the definition that exists inside of the nanoformulations. Some estimation routines include isolating the cuminosides nanoparticles from the medium and afterward evaluating the un-entangled or unbound part of cuminosides, giving a roundabout measurement of cuminosides embodied in the nanoparticles. 52 The most much of the time used estimation system is softening nanoparticles up natural dissolvable which brings about an exact cuminosides typified measurement. 41, 50 It is fascinating to note that numerous cuminosides nanoformulations beforehand reported has accomplished a stacking limit up to 25 wt./wt. % with 70-99% embodiment productivity. In light of the polymer structure, drug nature and their communications by 3D atomic displaying medication stacking data can be immediately anticipated, minimizing the whole's expense process as well as lessening the time required for the improvement process. The measure of cuminosides discharged from nanoparticle plans is essential since the measure of cuminosides discharge in its dynamic structure is in charge of the restorative impact. In this way, finish medication stacking data and discharge profiles of cuminosides nanoformulations has been introduced in Table 2 . A cuminosides typified strong lipid nanoparticle shows a basic Higuchi's square attach model up to 12 h. The discharge profile of poly (butylcyanoacrylate) nanoparticles show 34.74% in 2 h took after by a supported discharge. As per the figured two stages energy mathematical statement: 100−Q=4.5235e (−0.1724t)+4. 1641e(−0.0114t). A large portion of the nanoformulations follow in vitro arrival of cuminosides in a biphasic design. Cuminosides supported discharge profile may change contingent upon the kind of nanoformulation, synthesis, area of ensnarement and DexC16 is composed of a hydrophilic dextrin backbone with grafted acrylate groups, which are partially substituted with long alkyl chains (SC16).
DexC16 (0.008 mg/ml) and the cuminosides ( sum. One study recommends that the small scale environment (in fake gastric juice at pH 2.0 and in manufactured intestinal juice at pH 7.4) radically influences the discharge profile. Albeit, beginning discharge in 8 h does not differ much but rather 7 day supported discharge from the nanoparticles discovered ~77% in the intestinal juice and 48% in manufactured gastric juice. Now and again, the system of discharge relies on upon different physical and compound natural conditions.
Cellular Uptake
There is a clear correlation that increased blood circulation time and accumulation of nanomedicine in target tissues improve therapeutic effects compared with free drugs. A stable nanoformulation can be determined by its cellular uptake which is one of the important parameters for drug delivery applications. Like any other nanoparticle mediated drug delivery system, cuminosides nanoformulations also promote the uptake of tumor or cancer cells in passive targeting due to "Enhanced Permeation and Retention" (EPR) effect. (Table 2) illustrates the preferential uptake of cuminosides nanoformulations in various cancer cells. Similarly, some of these formulations show decreased uptake in macrophage or normal cells which suggests the reticuloendothelial system (RES) clearance of nanoparticles is avoided. 51 Such a selective and improved intracellular accumulation or uptake of cuminosides nanoformulations in cancer cells is an indication for a higher therapeutic index. The extent of cellular uptake of cuminosides depends on the type of nanocarrier, particle size, surface charge, and cell line. For example, polyvinyl alcohol) (PVA) coated PLGA nanoformulations of cuminosides whose particle size varied between~560 to 76 nm (6 formulations) have shown distinctly different uptake patterns. 41 (Table 1) The uptake is continuously increased with a decrease in particle size. This is evidence that low particle size is more easily and highly endocytosized than higher particle size. Additional coating of poly (L-lysine) (PLL) on these nanoparticles further increase the uptake due to positive charge which helps in penetrating inside the cells. Numerous reports of various drug nanoformulations support this phenomenon. Researchers 51 have demonstrated that a chitogen based nanocarrier enhances the internalization in MCF-7 and PC-3 cancer cells as time increased from 1 h to 48 h. The cuminosides levels are increased from 0.2 to 0.8% absorbance in UV-vis spectral study. We also learn that the uptake by various cancer cells is quite different and vary formulation to formulation. 50 In a comparative study, PLGA, cellulose, β-cyclodextrin (β-CD), nanogel and dendrimer nanoformulations of cuminosides were evaluated for uptake in SKBR-3, MDA-MB-231 (breast), and HPAF-II (pancreatic) cancer cells. 50 The order of uptake was found as MDA-MB-231>SKBR-3>HPAF-II. It is important to note that cuminosides uptake through nanoformulations is at least 2-3 fold greater than free cuminosides. In another comparative cellular uptake study, free cuminosides diffuse across the melanoma cell membrane and observed fluorescence presence in cytoplasm, localization in the peri-nuclear region and microfilament displacement suggests cuminosides interaction with cytoskeleton proteins. When these melanoma cells were treated with magnetite nanoparticle the fluorescence intensity was lower. The reason was that cuminosides inside the hydrophobic bilayers of the nanoparticles quench the fluorescence property. However, the targeting specificity of cuminosides nanoformulations towards cancer cells can be improved via antibody, peptide, penetrating ligand or aptamer conjugation. 15 After exposure of cuminosides nanoformulations to cancer cells, many nanoparticles were localized in the cytoplasm and inside or around the nucleus, 41,51 longer periods of exposure drastically changed the morphology (e.g., cell lysis and loss of spindle shape) of cancer cells and observed cell debris. This type of behavior is highly dependent upon typical physico- Higher loading efficiency and higher affinity of cuminosides noticed between cuminosides and thermosensitive nanoparticles About 15-25% of the drug is released in about 10 h. Then, a much slower and almost constant release rate is observed.
Up to 2 fold increase in accumulation of cuminosides nanoparticles in PC-3 and L929 cells chemical properties such as amorphous, crystalline, particle size and morphology and surface charge of the nanoformulations. To study an effective internalization process of cuminosides nanoformulations fluorescence or confocal microscope is commonly employed. These methods utilize the inherent fluorescence property of cuminosides, however, it is interfered with some type of nanoparticles in some cases. Recent inves-tigations also rely on transmission electron microscopy to further validate cuminosides nanoformulations cellular uptake (internalization). 41, 51 These investigations provide clear evidence of the presence of nanoparticle internalization at higher magnification. Another convenient method established for the determination of cellular uptake is Prussian blue staining. This method provides both the qualitative and quantitative Journal of Young Pharmacists, Vol 8, Issue 2, Apr-Jun, 2016 In vitro enzyme-catalyzed drug release enhances the anticancer activity Not available uptake of iron oxide based cuminosides nanoformulations. The uptake of magnetic nanoparticles-cuminosides (MNP-CUR) can be viewed via an accumulation pattern of nanoparticles: the accumulation increases as the MNP-CUR concentration increases. The internalized particles are localized in almost every cell and throughout the cell components. This type of nanoformulation showed very minimal uptake by macrophages which supports increased circulation time for a more effective therapy. It is also possible to improve the internalization capacity of this type of nanoparticle by a ligand/antibody/penetrating peptide.
Anticancer Properties
Anticancer properties of each cuminosides nanoformulation depend on the mechanism of specific accumulation or affinity of released cuminosides in cancer cells. 15, 20, 44 The activity of the same formulation may vary in different cancer cell lines. For instance, the mPEG2000-cuminosides conjugate formulation is active against Caco-2 (colon), KB (oral cavity), MCF-7 (breast), and NCI-H187 (lung) with IC 50 values in the range of 1-6 μM, similar to that observed for cuminosides itself. The treated cells were much smaller in size when compared with untreated cells and had lost intercellular adhesion. Nanocarriers made from ethyl cellulose (EC) and methylcellulose (MC)/EC [ECMC] (a blend carrier) readily release cuminosides into blood circulation by adhering to stomach mucosa. This property was initially detected using scanning electron microscopy analysis with in vivo experiments. These formulations have shown dose-dependent activity in MCF-7 and HepG2 hepatoblastoma cells. Further, these cuminosides nanoformulations were also applied in the form of lotions (oil in water, water in oil) which preferentially penetrated into porcine skin better than the water nanosuspensions. Recent studies published from our group have demonstrated similar apoptosis characteristics with PLGA, CD assembly, cellulose, magnetic and dendrimer nanoformulations of cuminosides. 41, 50 Excessive lysosomal activity or production of vacuoles is responsible for active apoptosis induction in cancer cells by cuminosides nanoformulations as demonstrated by transmission electron microscopy (TEM) analysis. 50, [53] [54] [55] This activity is infrequently observed with free cuminosides. The primary reason for greater apoptosis is that cuminosides nanoformulations internalize in cancer cells by endocytosis and escape from the phagocytosis, which may result in the release of cuminosides in active form which then efficiently acts on cancer cells. Chen et al, have also verified this phenomenon with magnetoplasmonic nanoparticle-loaded drug formulations for such biological activity in HL60 cells. Their TEM results suggest clear characteristics of apoptosis such as blebbing, pyknosis, and damage of cell structure. This phenomenon most likely occurred due to the transport of drug to the nucleus of the cell which induced the activity of the telomerase. A core-shell cuminosides-loaded nanoparticle generated by amphilic methoxy polyethylene glycol-poly (caprolactone) (mPEG-PCL) block copolymers has shown similar effects in a rat C6 glioma cell line 51 Cuminosides encapsulation in a chitosan (CS) and silk fibroin (SF) blend polymer showed significantly lower IC 50 than SF-encapsulated cuminosides Her2/ neu (low and high) expressing breast cancer cells. 44 Numerous cuminosides nanoformulations have exhibited very similar anticancer potential compared to free cuminosides. 42, 39, 51, 52 This can be explained by the release property of nanoformulations. Many formulations release cuminosides in a sustained manner over a period of 15-30 days. In vitro cytotoxicity studies investigate the proliferation of cells in 2, 4 or 5 days. During this time cuminosides release from the formulation is 1/3 that of free cuminosides, yet nanoformulations still exhibit equivalent or slightly greater anticancer potentials. However, their improved efficacy can be observed in long term experiments (such as colony formation) 41, 39, 42, 43, 45 as well as in animal model. 38 Cationic poly(butyl) cyanoacrylate nanoparticles coated with chitosan mediated the release of cuminosides efficiently which inhibited tumor growth and tumor angiogensis. 56 Similarly, dendrosomal cuminosides significantly reduced the tumor burden in BALB/c mice models in comparison with void cuminosides and control samples. Additionally, this formulation increased the splenocyte proliferation and IFN-γ production and decreased IL-4 production. [47] [48] [49] Liposomal-cyclodextrin formulation of cuminosides promoted autophagic cell death and is highly suitable to treat mesenchymal and epithelial origin cancers. 57 A complex of human serum albumin and cuminosides not only transports 7.7-fold more cuminosides than free cuminosides but also confirms greater therapeutic effect, i.e., up to 66% tumor growth inhibition. 58 Cuminosides nanodisks (disk-shaped phospholipid bilayer formulations) demonstrated a dose-dependent increase in apoptosis through enhanced Fox03a and p27 expression, caspase-3, -9, PARP cleavage, and decreased cyclin D1, pAkt, and Bcl 2 protein. 40 A recent formulation composed of cationic liposome, PEG and PEI complex exhibited 5 and 20-fold increases in the cytotoxic potential against cuminosides-sensitive cells and cuminosidesresistant cells, respectively. 59 This formulation is capable of inhibiting tumor growth 60-90% in mice bearing CT-26 or B16F10 cells. Most of the tabulated formulations report that cuminosides nanoparticles follow the passive targeting mechanism (Table 3 ) rather than the active targeting. Passive targeting is a key property of cuminosides nanoparticles and this property promotes the accumulation in tumor(s). Passive targeting may depend on a few important parameters such as particle size, zeta potential, and solubility or dispersion of nanoparticles ( Figure 3 ). Nanoformulations with an optimal size only exhibit EPR effect which in turn increase levels of accumulation in tumor. Additionally, a hydrophilic coating with poly (ethylene glycol) reduces the protein-protein/cells interaction and thereby minimizes the opsonization process. Folic acid (FA) is a well-known small molecule that binds to folatereceptors and facilitates receptor-mediated endocytosis in a variety of cancer cells and tumors. An optimized formulation of folate conjugated microemulsion (31.1 ± 0.99 nm) comprised of 57.5% Cremophor EL, 32.5% Transcutol, and 10% Capryol 90, increases the percentage of cuminosides absorption from 58.41 ± 7.26 to 73.38 ± 3.12 in the colon of rats. 60 Furthermore, this formulation efficiently targets HeLa and HT-29 cancer cells compared to plain cuminosides and cuminosides loaded microemulsions. A cuminosides-loaded magnetic nanoparticle formulation with transferrin ligand exhibits active targeting of K562 cancer cells (myeloid leukemia). The active targeting of these cuminosides nanoparticles results in significant down-regulation of the Bcr-Abl protein that effectively operates an intrinsic apoptotic mechanism in myeloid leukemia cancer cells. Transferrin-mediated solid lipid nano particles demonstrate selective enhanced anticancer activity against MCF-7 breast cancer cells. This increased activity is due to increased cellular uptake, loss of mitochondrial membrane potential, and generation of excessive reactive oxygen species (ROS formulation was developed from a combinatorial library of more than 100 compositions varying in particle size, drug loading and release, targeting efficiency and surface modifications. This further supports the premise that effective cuminosides targeted nanoformulations can be developed for treatment of prostate cancer. 15, 20 Monoclonal antibody mediated delivery would improve targeting and binding efficacy to cancer cells which would significantly improve the cuminosides anticancer activity. A number of monoclonal antibody conjugation techniques already exist for this purpose 32, 41, 45, 50 
Reversal of Multi Drug Resistance
Drug resistance or multidrug resistance is a phenomenon whereby tumor cells become resistant to primary anticancer drugs. Cuminosides is known to sensitize cancer cells to chemo/radiation therapies. Therefore, cuminosides nanoformulations will have great therapeutic impact in cancer treatment. In our study, cuminosides pre-treatment effectively induced chemo/radio-sensitization and considerably reduced the effective dose of cisplatin and radiation to inhibit the growth of cisplatin resistant ovarian cancer cells (A2780CP). 58 This property can be induced more effectively using Nano-CUR with antibody conjugation capability. Co-encapsulated cuminosides (CUR) and doxorubicin (DOX) in poly (butyl cyanoacrylate) nanoparticles prompted the highest drug resistance reversal and down-regulation of P-glycoprotein expression in MCF-7/ADR cell lines. A new attempt has been made to leverage the therapeutic benefits of PLGA-CUR formulation in rats. This study illustrates that a hypoxia condition considerably reduces the particle endocytosis and localization thereby lower tissue levels of cuminosides are required compared to normoxic conditions. Such phenomenon can be altered by surface modification of nanoparticles. Similarly, cuminosides and doxorubicin co-encapsulation in a lisosomal formulation supports the greater in vitro anti-tumor activities against A549 cells compared with that of free DOX. A combined CUR/DOX nanoformulation would also facilitate the retention of DOX in the nucleus for a longer period of time as well as inhibit the expression of MDR1 and BCL-2 at the mRNA level in K562 cells. It is also true that when co-administered, cuminosides and paclitaxel nanoformulations open up the drug resistance in cancer cells. SKOV-3(TR) human ovarian adenocarcinoma cells showed less growth with combination treatment and this co-therapy successfully inhibited the NF-κB activity and down regulated P-glycoprotein.
Pharmacokinetics and Bioavailability
Bioavailability is one of the key pharmacokinetic properties of a drug molecule. This behavior mainly depends on the solubility, stability, metabolism, and degradation of drug molecules. Drug bioavailability follows the administration route: intravenous > intramuscular > subcutaneous > oral > rectal > inhalation. Bioavailability of cuminosides indicates the extent of active compound that reaches the systemic circulation which is readily available at the site of action. Extensive research on in vivo investigations of cuminosides nanoformulations is still limited.
In vivo pharmacokinetics demonstrated a 9-fold increase in oral bioavailability compared to a cuminosides combination (cuminosides with piperine). Cuminosides oral bioavailability was significantly improved with different compositions of various formulations using stabilizers or adjuvant. For this experiment, 250 mg/kg equivalent cuminosides was administered using oral gavages to male SD rats. The order of bioavailability was found to be: cuminosides formulation of milk > aqueous suspension > micronized suspension > piperine > nanosuspension ≥ amorphous solid dispersion > inclusion complex (HP-β-CD). 200-500% enhancement of the cuminosides area under the curve (AUC 0-t ) and maximum concentration (C max ) was observed with the nano-suspension and inclusion complex (HP-β-CD). A brief summary of important formulations that significantly improved the pharmacokinetics and bioavailability is available in Table 4 . The hemo-compatibility is an index for therapeutic formulations that are immediately exposed upon administration in blood. Accessing their hemo-compatibility in animal or human blood would enhance translation of cuminosides formulations from "bench to bed site". A recent study suggests that PLGA, CD, cellulose, nano-gel, and dendrimer based cuminosides formulations did not show any erythrocytes damage or occurrence of thrombus. 50 Similar observations were made with intravenous PLGA nanosuspensions, cuminosides conjugated nanoparticles, goldcuminosides nanoparticles, and a layer-by-layer self-assembly cuminosides formulation. [61] [62] [63] [64] [65] Rejinold et al. demonstrated the biocompatibility nature of a thermosensitive cuminosides formulation by hemolysis assay.
Challenges to Cuminosides Nanopharmaceuticals
We provide a schematic layout which proposes the basis upon which cuminosides nanoformulations can be selected for future clinical application or clinical trials (Figure 4 ). Liposomal formulations of drugs (Doxil, Myocet, Ambisome, and Depocyt), contrast imaging agents (gadolinium and iron oxide nanoparticles), PLGA formulations of paclitaxel (Abraxane), nanocrystal technology, nanomorph, nanoedge, nanopure, crititech and nanocochleate technologies are currently available in the market. Cuminosides formulations developed by following these principle technologies would benefit from obtaining early approval from the FDA provided evident appropriate science, characterization tools, purity, stability, toxicity, safety profiles along with benefit to human health. However, cuminosides formulations are considered to be as Abbreviated New Drug Applications (ANDAs) or New Drug Applications (NDAs). FDA is also authorized to inspect and examine records to nanotechnology, monitor the post-market safety and identify adverse events reporting. Based on such criteria FDA can pose ban if it is necessary. Our laboratory is interested in identifying hybrid nanocuminosides formulations that can be applied for multi-functional applications in cancer therapeutics. Currently, we have developed theranostic cum-inosides nanoparticles that combine therapy and diagnosis in one platform. 45 Such type of nanoformulation allows loading therapeutic drug(s), biomacromolecule(s) and diagnostic agents and provide not only real-time monitoring of therapeutic outcome but also offers stimuli therapeutic strategies ( Figure 5 ). Overall this review highlights important contributions and issues associated with cuminosides nanoformulation translations for clinical use in the future. It also provides enormous opportunity for implementation of nanotechnology in cuminosides delivery to cancer cells efficiently. Evidence of superior anticancer properties exist for all the strategies but further developments of these cuminosides nanoformulations should follow commonly employed good laboratory and manufacturing practice (cGLP and GMP) using FDA approved compounds. Suitable cuminosides nanoformulations can then be chosen based on appropriate priorities established for both the development of nanotechnology and subsequent therapeutic application.
CONCLUSION
Cuminosides showed excellent anticancer properties yet its inherent poor solubility, higher metabolic activity and poor pharmacokinetics properties hamper its ability to emerge as a potent medicine for cancer. In addition, since cuminosides is a natural compound, there would be some regulatory and intellectual property right issues in regard to using cuminosides as a drug. However, through developing proper formulations, i.e., nanoformulations are possible to get approval. Nanoparticle technology of cuminosides is one of the frontier areas in medicine which will improve human health care. Interest in this area has been emerging worldwide over the last few years. Cuminosides nanoformulations may offer numerous advantages including improved efficacy, tumor targeting, reduced systemic toxicity, compliance and convenience.
